Cargando…
What do oncologists need to know about biosimilar products?
Many biologic products have improved the outcomes of cancer patients, but the costs can substantially burden healthcare systems. Biosimilar products can potentially reduce drug costs and increase patient access to beneficial treatments. Approval of a biosimilar product relies on the demonstration of...
Autores principales: | Leung, Linda K. S., Mok, Kevin, Liu, Calvin, Chan, Stephen L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062853/ https://www.ncbi.nlm.nih.gov/pubmed/27733189 http://dx.doi.org/10.1186/s40880-016-0151-x |
Ejemplares similares
-
How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
por: Triplitt, Curtis, et al.
Publicado: (2017) -
What the oncologist needs to know about COVID-19 infection in cancer patients
por: Rassy, Elie, et al.
Publicado: (2020) -
Biosimilar Insulins – What a Clinician Needs to Know?
por: Ghosh, Sujoy, et al.
Publicado: (2019) -
Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
por: Azevedo, Valderilio Feijó, et al.
Publicado: (2019) -
The gut microbiome: what the oncologist ought to know
por: Lee, K. A., et al.
Publicado: (2021)